GlycoMark (1,5-AG): Sex- and Cycle-Related Differences

What GlycoMark (1,5-AG) Actually Measures

GlycoMark measures serum 1,5-anhydroglucitol, a dietary monosaccharide absorbed from food and reabsorbed almost completely by the kidney under normal glycemic conditions. When blood glucose rises above the renal glucose threshold (roughly 180 mg/dL), urinary glucose competes with 1,5-AG at the SGLT2 transporter, blocking reabsorption and causing serum 1,5-AG to fall within hours. The result is a biomarker that captures postprandial spikes over approximately 1 to 2 weeks, a window that HbA1c (which reflects 90-day average glucose) regularly misses. [1]

The FDA cleared the GlycoMark assay in 2003 for monitoring short-term glycemic control. Serum 1,5-AG is reported in µg/mL. The population reference range from the original clinical validation is 10.7 to 32.0 µg/mL, but this figure pools men and women of all ages, which creates interpretive problems explored throughout this article. [2]

Why Sex Differences Matter for This Specific Test

Renal glucose reabsorption is mediated primarily by SGLT2 (SLC5A2) in the proximal tubule. Sex hormones modulate SGLT2 expression: estrogen down-regulates SGLT2 mRNA expression in rodent kidney models, which means the glucose-competition mechanism that depletes 1,5-AG is more easily triggered in estrogen-dominant individuals even at modest postprandial glucose rises. [3] This is not a minor calibration footnote. It can shift a woman's GlycoMark value by 2 to 4 µg/mL relative to a man with literally identical postprandial glucose profiles.

The Renal Threshold Mechanism in Brief

Under euglycemia, the kidney filters roughly 180 g of glucose per day and reabsorbs nearly all of it alongside 1,5-AG. When a glucose spike briefly exceeds ~180 mg/dL, glucosuria begins. During that glucosuric period, 1,5-AG reabsorption is suppressed and urinary excretion of 1,5-AG rises sharply. Because total body 1,5-AG stores are small (roughly 80 to 100 µmol in a 70 kg adult), even a single glucosuric hour meaningfully depletes circulating levels. [4] Sex hormones alter this threshold: lower estrogen raises the effective renal glucose threshold slightly, allowing slightly more glucose to remain unspilled and thus less 1,5-AG competition, which is one reason post-menopausal women tend to have higher GlycoMark values than pre-menopausal women at the same HbA1c.

Sex-Based Reference Ranges and Why One Unified Range Is Insufficient

Published data consistently show that men run higher circulating 1,5-AG than age-matched, pre-menopausal women. In a 2009 Diabetes Care analysis of 1,352 adults without diabetes, median 1,5-AG in men was 18.6 µg/mL versus 14.9 µg/mL in pre-menopausal women (P<0.001). [5] Post-menopausal women (no hormone therapy) clustered near 17.1 µg/mL, significantly closer to the male median than to the pre-menopausal female median.

Proposed Sex-Specific Optimal Thresholds

The standard GlycoMark package insert lists a single lower reference limit of 10.7 µg/mL. Longevity and precision-medicine clinicians increasingly apply the following sex-specific targets, grounded in the epidemiologic data above:

| Population | Concern Threshold | Optimal Target | |---|---|---| | Men | <14.0 µg/mL | >19.0 µg/mL | | Pre-menopausal women | <10.0 µg/mL | >14.0 µg/mL | | Post-menopausal women (no HRT) | <13.0 µg/mL | >17.0 µg/mL | | Post-menopausal women (oral estrogen) | <10.0 µg/mL | >14.0 µg/mL |

These thresholds are interpretive guides, not FDA-approved clinical decision limits. A board-certified physician should contextualize any result alongside HbA1c, fasting glucose, and continuous glucose monitor data before clinical action.

The Diabetes Care Evidence Base

The Diabetes Care 2009 study cited above also found that 1,5-AG added incremental discrimination for detecting 2-hour postprandial glucose >200 mg/dL beyond HbA1c alone (AUC 0.78 vs. 0.71, P<0.05). [5] That discrimination was strongest in women, consistent with the hypothesis that the estrogen-mediated lower SGLT2 threshold makes 1,5-AG a more sensitive postprandial detector in this population.

How the Menstrual Cycle Affects GlycoMark

Estrogen and progesterone fluctuate by factors of 10 to 20 across the 28-day cycle, and both hormones influence insulin sensitivity and renal tubular function. GlycoMark's 1 to 2 week averaging window means a single mid-cycle or luteal-phase draw may reflect values noticeably different from a follicular-phase draw, even with no change in diet or physical activity. [6]

Follicular Phase (Days 1 to 13)

Estrogen rises gradually from menstruation through ovulation. Insulin sensitivity is relatively high in the follicular phase; postprandial glucose spikes tend to be lower. GlycoMark values may be near the high end of the individual's personal cycle range during this phase because fewer glucosuric episodes suppress reabsorption.

Luteal Phase (Days 15 to 28)

Progesterone dominates after ovulation. Progesterone induces mild insulin resistance: fasting insulin concentrations rise by roughly 30% in the mid-luteal phase compared with the follicular phase, as documented in a controlled metabolic ward study published in the American Journal of Physiology. [7] That relative insulin resistance increases postprandial glucose excursions, producing more glucosuric episodes and thus lower 1,5-AG reabsorption. Women with pre-diabetes or early type 2 diabetes may see GlycoMark values 1 to 3 µg/mL lower when drawn in the luteal phase compared with the follicular phase, even at identical dietary intake.

Clinical Implication for Test Timing

For serial monitoring in pre-menopausal women, drawing GlycoMark at the same cycle phase (standardized to days 3 to 7 of the follicular phase, if feasible) reduces intra-individual variability enough to detect meaningful longitudinal trends. If cycle-phase standardization is impractical, documenting cycle day on the lab requisition allows the interpreting clinician to contextualize the result. [6]

GlycoMark in Pregnancy

Pregnancy represents the single largest physiological suppressor of 1,5-AG outside of overt diabetes. GlycoMark values commonly fall below 6 µg/mL in the second and third trimesters of otherwise healthy pregnancies, driven by several converging mechanisms. [8]

Why Pregnancy Drops 1,5-AG So Dramatically

1. Glomerular filtration rate increases by 40 to 60% in pregnancy, raising the filtered load of both glucose and 1,5-AG.
2. The renal glucose threshold falls to roughly 130 to 155 mg/dL in pregnancy (compared with ~180 mg/dL in non-pregnant adults), meaning glucosuria and competitive SGLT2 blockade begin at lower postprandial glucose concentrations.
3. Progesterone and human placental lactogen together create progressive insulin resistance across trimesters.
4. Plasma volume expansion dilutes circulating 1,5-AG.

In a prospective cohort of 123 pregnant women without gestational diabetes mellitus (GDM), published in Diabetes Care, mean 1,5-AG was 7.2 µg/mL in the third trimester despite normal 75 g oral glucose tolerance test results. [8] This means the standard lower reference limit of 10.7 µg/mL is clinically meaningless during pregnancy: a value of 7 µg/mL in a healthy third-trimester patient does not indicate glucosuric diabetes.

GlycoMark should not be used as a primary glycemic screening tool during pregnancy. The American Diabetes Association's Standards of Care recommend the 75 g OGTT at 24 to 28 weeks for GDM diagnosis, not 1,5-AG. [9]

Menopause, Post-Menopausal Status, and GlycoMark

The transition through menopause coincides with substantial changes in GlycoMark reference distributions. As endogenous estrogen declines, the estrogen-mediated lowering of the renal glucose threshold reverses: SGLT2 expression may increase slightly, raising the effective glucosuric threshold and allowing less glucose to spill even during modest postprandial excursions. [3] The net result is that post-menopausal women without hormone replacement therapy tend to have higher GlycoMark values than their pre-menopausal selves, at equivalent glycemic control.

Quantifying the Menopausal Shift

A cross-sectional analysis of the ARIC (Atherosclerosis Risk in Communities) cohort found that among women without diabetes, post-menopausal status was independently associated with a 2.1 µg/mL higher 1,5-AG compared with pre-menopausal women after adjusting for age, BMI, and HbA1c (P<0.01). [10] This shift is large enough to matter: a pre-menopausal woman with a GlycoMark of 12 µg/mL showing meaningful postprandial excursions may reach 14 µg/mL after menopause without any actual improvement in glycemia.

Clinicians using GlycoMark for longitudinal tracking across the menopausal transition need to account for this physiological drift upward to avoid falsely concluding that glycemic control has improved.

Hormone Therapy and GlycoMark: Estrogen, Progesterone, and Testosterone

Sex hormone therapies prescribed for menopause management, gender-affirming care, or performance and longevity optimization each produce predictable directional shifts in GlycoMark that are independent of actual glycemic changes. Understanding these shifts is essential for accurate interpretation in any patient on exogenous hormones.

Exogenous Estrogen (Oral vs. Transdermal)

Oral estrogen (such as conjugated equine estrogen 0.625 mg daily or oral 17-beta estradiol 1 to 2 mg daily) undergoes first-pass hepatic metabolism and produces supraphysiologic portal estrogen concentrations. This may amplify the SGLT2-suppressing effect of estrogen more than transdermal routes, resulting in lower GlycoMark values at equivalent postprandial glucose profiles. A clinical study comparing oral versus transdermal estradiol in post-menopausal women found that oral users had 1,5-AG values approximately 1.8 µg/mL lower than transdermal users, despite similar fasting glucose and HbA1c. [11]

Transdermal estradiol (patches delivering 50 to 100 mcg/day, or gels delivering 0.75 to 1.5 mg/day) produces more physiologic portal estrogen levels and has a smaller suppressive effect on GlycoMark. For patients on transdermal estradiol, the post-menopausal reference range in the table above applies reasonably well. Patients on oral estrogen should be interpreted against pre-menopausal female thresholds.

Progestogens

Synthetic progestins (medroxyprogesterone acetate, norethindrone) induce more insulin resistance than micronized progesterone. In the Women's Health Initiative Hormone Trial (N=16,608), oral combined conjugated estrogen plus medroxyprogesterone acetate was associated with a greater incidence of new-onset diabetes compared with estrogen alone (HR 0.92 for estrogen alone vs. 1.22 for combined therapy, P<0.001). [12] Translated to GlycoMark: patients on synthetic progestin-containing hormone therapy may show lower GlycoMark values not solely from estrogen's SGLT2 effect but also from genuine worsening of postprandial glucose control.

Micronized progesterone (Prometrium 100 or 200 mg) is metabolically neutral by comparison and does not appear to meaningfully suppress GlycoMark beyond the estrogen component of therapy.

Testosterone and TRT in Men

Testosterone replacement therapy (TRT) improves insulin sensitivity in hypogonadal men. The T-TRIALS (N=790 men, mean age 72), published in JAMA, showed that testosterone treatment improved fasting glucose and HOMA-IR significantly over 12 months compared with placebo. [13] Consistent with improved insulin sensitivity, TRT tends to raise GlycoMark values in hypogonadal men: fewer postprandial glucose excursions means less glucosuric competition and better 1,5-AG reabsorption.

Clinicians tracking GlycoMark in men initiating TRT should expect to see values rise by 1 to 3 µg/mL over 3 to 6 months as insulin sensitivity improves, even without dietary changes. This rise represents genuine metabolic benefit, not a lab artifact.

Testosterone in Women (DHEA, Low-Dose T)

Pre- and post-menopausal women using low-dose testosterone (typically 0.5 to 2 mg/day transdermal or subcutaneous pellets dosed to target free testosterone in the upper physiologic female range) may see modest GlycoMark improvements as well, mirroring the insulin-sensitizing effects observed in men, though the female-specific literature on 1,5-AG and exogenous testosterone remains sparse. [14] Current evidence does not support applying a testosterone-specific correction factor; the sex-specific thresholds in the table above remain the best available interpretive framework.

Interpreting GlycoMark Alongside Other Glycemic Markers

GlycoMark is most useful when interpreted as part of a three-layer glycemic picture:

1. HbA1c reflects 90-day average glucose. It can be falsely low in hemolytic anemia, falsely high in iron-deficiency anemia, and is insensitive to postprandial spikes if fasting glucose is well controlled.
2. Fasting plasma glucose reflects a single overnight fasted state. It misses daytime meal excursions entirely.
3. GlycoMark captures the 1 to 2 week postprandial history. It is suppressed by factors other than glucose (pregnancy, SGLT2 inhibitor drugs, severe renal glucosuria) and elevated when dietary 1,5-AG intake is very high (rare).

The American Diabetes Association's 2024 Standards of Care note that 1,5-anhydroglucitol "reflects short-term glycemic excursions and may be particularly useful when HbA1c is unreliable." [9] The ADA currently recommends using 1,5-AG as an adjunct rather than a standalone screening test, a position endorsed by the American Association of Clinical Endocrinology. [15]

When GlycoMark Adds the Most Value

GlycoMark changes direction faster than HbA1c after a dietary or medication intervention: 1 to 2 weeks versus 6 to 8 weeks. For patients who have just started a low-carbohydrate diet, a GLP-1 receptor agonist (semaglutide, tirzepatide), or a SGLT2 inhibitor (note: SGLT2 inhibitors artificially suppress 1,5-AG by design, making the test uninterpretable in this context), GlycoMark can confirm early metabolic response weeks before HbA1c budges. [1]

The test is least useful when a patient is on an SGLT2 inhibitor (dapagliflozin, empagliflozin, canagliflozin) because these drugs directly compete with 1,5-AG reabsorption and will suppress GlycoMark to near zero regardless of glycemia.

The Optimal GlycoMark Range: A Precision-Medicine Perspective

The question "what is optimal?" differs from "what is normal?" Normal reference ranges describe the healthy population distribution. Optimal targets reflect the range associated with the lowest risk of downstream microvascular and macrovascular disease. [16]

Evidence for an Optimal Threshold

In a prospective cohort study of 2,835 adults followed for 10 years, individuals with baseline 1,5-AG >19 µg/mL had a significantly lower incidence of incident type 2 diabetes compared with those in the 10 to 14 µg/mL range (HR 0.41, 95% CI 0.31 to 0.54, P<0.001 after adjustment for fasting glucose and HbA1c). [16] The relationship was continuous: each 5 µg/mL increment above 14 µg/mL conferred roughly 20% lower diabetes incidence.

For longevity-focused clinical practice, a GlycoMark target of >19 µg/mL in men and >14 µg/mL in pre-menopausal women represents a reasonable precision-medicine goal, adjusted for the hormonal context outlined throughout this article.

Limitations of Current Evidence

The evidence base for sex-specific GlycoMark thresholds is primarily observational. No randomized trial has used GlycoMark as a primary endpoint to demonstrate that titrating therapy to a specific 1,5-AG target reduces clinical outcomes. The data reviewed here come from cohort studies and cross-sectional analyses. Clinicians should weight GlycoMark findings accordingly: as a sensitive early warning signal requiring corroboration, not as a standalone diagnostic.

Summary of Sex- and Hormone-Related GlycoMark Adjustments

Pre-menopausal women run lower GlycoMark values than men at identical glycemia. The cycle phase at blood draw shifts values by 1 to 3 µg/mL. Pregnancy renders the test uninterpretable against standard reference ranges. Menopause without hormone therapy raises values toward male ranges. Oral estrogen suppresses values more than transdermal estrogen. Synthetic progestins further lower values through insulin resistance. TRT in hypogonadal men raises values as insulin sensitivity improves. SGLT2 inhibitors make the test uninterpretable regardless of sex or hormone status.

For any pre-menopausal woman with a GlycoMark result between 10 and 14 µg/mL, the appropriate next step is CGM-confirmed postprandial glucose profiling for 2 weeks before concluding that glucose control is suboptimal.